Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Press Releases

Filter articles using the following links
  • Financial press releases
  • Events & presentations
10 Aug 2017

Ophthalmology Innovation Summit @ ASRS, Boston (MA)

01 August 2017

GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

28 July 2017

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

23 June 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

23 June 2017

GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

22 June 2017

GenSight Biologics launches a capital increase of approximately €20 million

19 Jun 2017 - 22 Jun 2017

BIO International Convention, San Diego, CA (US)

14 June 2017

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

30 May 2017

15ème Forum Santé Gilbert Dupont, Paris (France)

28 May 2017 - 31 May 2017

ISCAS 2017, Baltimore, Maryland (US)

  • View previous 9 articles
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 42
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page